NCT05977088 · RECRUITING
Prediction of Effectiveness of rTMS Application in Alzheimer's Patients
This trial is testing whether repetitive transcranial magnetic stimulation (rTMS) — a non-invasive device that uses magnetic pulses to stimulate the brain — can help people already diagnosed with Alzheimer's disease. Researchers are also drawing blood before and after treatment to look for biological changes. This is a Phase NA, or exploratory, study focused on predicting who responds best to rTMS, not a large-scale effectiveness trial.
You may qualify if
- Have been diagnosed with clinical Alzheimer's Disease in accordance with the NINCDS-ADRDA diagnostic criteria
- >55 years old
- Clinical Dementia Rating Scale (CDR) score in the 1-2 range
- Not having any other disease that affects their cognitive functions
- Volunteer to participate in the study
You're excluded if
- Participant or relative does not give consent
- The patient's inability to participate in the entire study procedure (eg living in another city)
- The patient's history of head trauma with alcohol/substance abuse
- Presence of severe stroke and other neurological sequelae disease in the participant
- Presence of a metal implant on the head or having a pacemaker and contraindications for other TMS applications During the study or 1 month before, having/been receiving/receiving an investigational drug targeting Alzheimer's disease or neuromodulation treatment such as tDCS and TMS, other than standard treatment for AD symptom control such as acetylcholine esterase and memantine, with the potential to affect the study
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2025-05-02